Top

Published in:

Open Access 01-01-2021 | Rituximab | Letter to the Editors

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

Authors: Marcel S. Woo, David Steins, Vivien Häußler, Matin Kohsar, Friedrich Haag, Birte Elias-Hamp, Christoph Heesen, Marc Lütgehetmann, Julian Schulze zur Wiesch, Manuel A. Friese

Published in: Journal of Neurology | Issue 1/2021

Excerpt

Dear Sirs, …

Available only for authorised users

Sormani MP (2020) An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30147-2CrossRefPubMedPubMedCentral

Long Q-X, Liu B-Z, Deng H-J et al (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. https://doi.org/10.1038/s41591-020-0897-1CrossRefPubMedPubMedCentral

Wölfel R, Corman VM, Guggemos W et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature. https://doi.org/10.1038/s41586-020-2196-xCrossRefPubMed

Lurie N, Saville M, Hatchett R, Halton J (2020) Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. https://doi.org/10.1056/nejmp2005630CrossRefPubMed

Wan Y, Shang J, Sun S et al (2019) Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 94:2015–2034. https://doi.org/10.1128/JVI.02015-19CrossRef

Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688. https://doi.org/10.1056/NEJMoa0706383CrossRefPubMed

Tahara M, Oeda T, Okada K et al (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298–306. https://doi.org/10.1016/S1474-4422(20)30066-1CrossRefPubMed

Title: Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
Authors: Marcel S. Woo
David Steins
Vivien Häußler
Matin Kohsar
Friedrich Haag
Birte Elias-Hamp
Christoph Heesen
Marc Lütgehetmann
Julian Schulze zur Wiesch
Manuel A. Friese
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Rituximab
SARS-CoV-2
Neuromyelitis Optica Spectrum Disease
COVID-19
Rituximab
Published in: Journal of Neurology / Issue 1/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10046-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine

The capacity to consent to treatment in amyotrophic lateral sclerosis: a preliminary report

Changes in the EEG spectral power during dual-task walking with aging and Parkinson’s disease: initial findings using Event-Related Spectral Perturbation analysis

The European Physiotherapy Guideline for Parkinson’s Disease: translation for non-English speaking countries

Impact of COVID-19 lockdown on sleep quality in university students and administration staff

Early discrimination of cognitive motor dissociation from disorders of consciousness: pitfalls and clues